Major investment in cell therapy : C3i is here!

The Networks of Centres of Excellence (NCE) of Canada announced this morning a 15 million dollars for a five year period for the creation of a new Centre of Excellence for Commercialization and Research (CECR). This new centre, the C3i, will help accelerate the access to novel therapies against cancer developping, translating and commercializing cancer immunotherapy.

“By harnessing the power of the immune system, we have the potential to revolutionize cancer treatment. These are game-changing therapies, and with this support C3i can work to ensure a brighter future for cancer patients. At the same time, Canada has the expertise in this area to become a world leader and take advantage of the tremendous business opportunity presented by immunotherapy. C3i will act as a catalyst to support this development.” – Lambert Busque, Chief Medical Officer, C3i

C3i will be based in Montreal and will operate from the Maisonneuve-Rosemont Hospital research centre, its host institution.

CellCAN welcomes this excellent news and wishes success to the new center!

- Read the press release
- Learn more about C3i